Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk
Richard Paul Green,1 Kenneth Blum,2– 5 Kai Uwe Lewandrowski,5,6 Mark S Gold,7 Alexander PL Lewandrowski,8 Panayotis K Thanos,2,9 Catherine A Dennen,10 David Baron,3,11 Igor Elman,2,12 Alireza Sharafshah,13 Edward J Modestino,14 Rajendra D Badgaiyan15 1Precision Translational Medicine, LLC, San Anton...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Substance Abuse and Rehabilitation |
| Subjects: | |
| Online Access: | https://www.dovepress.com/response-to-the-samhsa-clinical-advisory-considerations-for-genetic-te-peer-reviewed-fulltext-article-SAR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584050845417472 |
|---|---|
| author | Green RP Blum K Lewandrowski KU Gold MS Lewandrowski AP Thanos PK Dennen CA Baron D Elman I Sharafshah A Modestino EJ Badgaiyan RD |
| author_facet | Green RP Blum K Lewandrowski KU Gold MS Lewandrowski AP Thanos PK Dennen CA Baron D Elman I Sharafshah A Modestino EJ Badgaiyan RD |
| author_sort | Green RP |
| collection | DOAJ |
| description | Richard Paul Green,1 Kenneth Blum,2– 5 Kai Uwe Lewandrowski,5,6 Mark S Gold,7 Alexander PL Lewandrowski,8 Panayotis K Thanos,2,9 Catherine A Dennen,10 David Baron,3,11 Igor Elman,2,12 Alireza Sharafshah,13 Edward J Modestino,14 Rajendra D Badgaiyan15 1Precision Translational Medicine, LLC, San Antonio, Tx, USA; 2Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel; 3Center for Sports, Exercise, Global Mental Health, Western University Health Sciences, Pomona, CA, USA; 4Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; 5Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA; 6Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, DC, Colombia; 7Department of Psychiatry, Washington University, School of Medicine, St. Louis, Missouri, USA; 8Department of Biological Sciences, Dornsife College of Letters, Arts & Sciences, University of Southern California, Los Angeles, CA, USA; 9Behavioral Neuropharmacology and Neuroimaging Laboratory, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, Clinical Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA; 10Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA; 11Department of Psychiatry, Stanford University School of Medicine, Palo Alto, CA, USA; 12Department of Psychiatry, Harvard University School of Medicine, Cambridge, MA, USA; 13Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 14Brain & Behavior Laboratory, Department of Psychology, Curry College, Milton, Massachusetts, USA; 15Department of Psychiatry, Texas Tech University Health Sciences, School of Medicine, Midland, TX, USACorrespondence: Rajendra D Badgaiyan; Kenneth Blum, Email badgaiyan@gmail.com; drd2gene@gmail.com |
| format | Article |
| id | doaj-art-1d1257ddce51415cac03874360d37582 |
| institution | Kabale University |
| issn | 1179-8467 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Substance Abuse and Rehabilitation |
| spelling | doaj-art-1d1257ddce51415cac03874360d375822025-01-27T18:05:34ZengDove Medical PressSubstance Abuse and Rehabilitation1179-84672025-01-01Volume 16232699639Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder RiskGreen RPBlum KLewandrowski KUGold MSLewandrowski APThanos PKDennen CABaron DElman ISharafshah AModestino EJBadgaiyan RDRichard Paul Green,1 Kenneth Blum,2– 5 Kai Uwe Lewandrowski,5,6 Mark S Gold,7 Alexander PL Lewandrowski,8 Panayotis K Thanos,2,9 Catherine A Dennen,10 David Baron,3,11 Igor Elman,2,12 Alireza Sharafshah,13 Edward J Modestino,14 Rajendra D Badgaiyan15 1Precision Translational Medicine, LLC, San Antonio, Tx, USA; 2Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel; 3Center for Sports, Exercise, Global Mental Health, Western University Health Sciences, Pomona, CA, USA; 4Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; 5Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA; 6Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, DC, Colombia; 7Department of Psychiatry, Washington University, School of Medicine, St. Louis, Missouri, USA; 8Department of Biological Sciences, Dornsife College of Letters, Arts & Sciences, University of Southern California, Los Angeles, CA, USA; 9Behavioral Neuropharmacology and Neuroimaging Laboratory, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, Clinical Research Institute on Addictions, University at Buffalo, Buffalo, NY, USA; 10Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA; 11Department of Psychiatry, Stanford University School of Medicine, Palo Alto, CA, USA; 12Department of Psychiatry, Harvard University School of Medicine, Cambridge, MA, USA; 13Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 14Brain & Behavior Laboratory, Department of Psychology, Curry College, Milton, Massachusetts, USA; 15Department of Psychiatry, Texas Tech University Health Sciences, School of Medicine, Midland, TX, USACorrespondence: Rajendra D Badgaiyan; Kenneth Blum, Email badgaiyan@gmail.com; drd2gene@gmail.comhttps://www.dovepress.com/response-to-the-samhsa-clinical-advisory-considerations-for-genetic-te-peer-reviewed-fulltext-article-SARreward deficiency syndromegenetic addiction risk score (gars)substance use disorders (suds)dopaminesamhsa |
| spellingShingle | Green RP Blum K Lewandrowski KU Gold MS Lewandrowski AP Thanos PK Dennen CA Baron D Elman I Sharafshah A Modestino EJ Badgaiyan RD Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk Substance Abuse and Rehabilitation reward deficiency syndrome genetic addiction risk score (gars) substance use disorders (suds) dopamine samhsa |
| title | Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk |
| title_full | Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk |
| title_fullStr | Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk |
| title_full_unstemmed | Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk |
| title_short | Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk |
| title_sort | response to the samhsa clinical advisory considerations for genetic testing in the assessment of substance use disorder risk |
| topic | reward deficiency syndrome genetic addiction risk score (gars) substance use disorders (suds) dopamine samhsa |
| url | https://www.dovepress.com/response-to-the-samhsa-clinical-advisory-considerations-for-genetic-te-peer-reviewed-fulltext-article-SAR |
| work_keys_str_mv | AT greenrp responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT blumk responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT lewandrowskiku responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT goldms responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT lewandrowskiap responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT thanospk responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT dennenca responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT barond responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT elmani responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT sharafshaha responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT modestinoej responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk AT badgaiyanrd responsetothesamhsaclinicaladvisoryconsiderationsforgenetictestingintheassessmentofsubstanceusedisorderrisk |